NVAX Stock Overview
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.13 |
| 52 Week High | US$13.35 |
| 52 Week Low | US$6.77 |
| Beta | 2.09 |
| 11 Month Change | -10.68% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVAX | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 20.2% | 2.9% | -0.3% |
| 1Y | n/a | 5.3% | 2.5% |
Return vs Industry: Insufficient data to determine how NVAX performed against the Austrian Biotechs industry.
Return vs Market: Insufficient data to determine how NVAX performed against the Austrian Market.
Price Volatility
| NVAX volatility | |
|---|---|
| NVAX Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.6% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: NVAX's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: Insufficient data to determine NVAX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| NVAX fundamental statistics | |
|---|---|
| Market cap | €1.30b |
| Earnings (TTM) | -€273.55m |
| Revenue (TTM) | €850.05m |
1.5x
P/S Ratio-4.8x
P/E RatioIs NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVAX income statement (TTM) | |
|---|---|
| Revenue | US$885.19m |
| Cost of Revenue | US$769.73m |
| Gross Profit | US$115.46m |
| Other Expenses | US$400.32m |
| Earnings | -US$284.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 13.04% |
| Net Profit Margin | -32.18% |
| Debt/Equity Ratio | -32.2% |
How did NVAX perform over the long term?
See historical performance and comparison